Identification and characterization of novel Faecalibacterium prausnitzii strains from infant gut microbiota with potential pharmabiotic applications
Abstract
Faecalibacterium prausnitzii is a dominant commensal bacterium in the human gut, widely known for its production of bioactive metabolites and currently considered a potential pharmabiotic for the treatment of various human diseases. In this study, ten novel strains of Faecalibacterium prausnitzii were isolated from stool samples of Russian infants and characterized using whole genome sequencing and metabolomic analyses. Comparative genomic analysis revealed an open pangenome structure and significant strain-specific variability, reflecting the strains’ high adaptive potential within the human host and confirming the heterogeneity of this species. Four isolates (MSK-01, MSK-05, MSK-07, MSK-09) exhibited elevated butyrate production, and MSK-01 additionally displayed enhanced formate synthesis. The previously developed catalog of genes with anti-inflammatory, immune, and neuromodulatory activity was used for in silico analysis and targeted annotation of sequenced genomes. In silico analysis confirmed the presence of genes associated with anti-inflammatory, antioxidant, and neuromodulatory metabolites. Strains MSK-07 and MSK-09 were selected as the top candidates for development as infant pharmabiotics. These results expand on previously described findings on the genetic diversity of Faecalibacterium prausnitzii and identify promising strains with high pharmabiotic potential for future human therapy. These findings allow us to proceed to the next stages of selection and development of pharmabiotics for microbiome correction.
Related
- Evidence consistency analysis of the effect of a low-FODMAP diet on the abundance of Bifidobacterium and Faecalibacterium prausnitzii in patients with irritable bowel syndrome
- Identification and characterization of two transmembrane proteins required for virulence of Ustilago maydis
- Comprehensive identification, characterization, and stress response analysis of the ZmSPL gene family in maize (Zea mays L.)
- Identification and characterization of inflammatory LILR and fibrotic SPP1 macrophages in chronic lung allograft dysfunction
- Genome-Wide Identification and Functional Characterization of the Carboxylesterase (CXE) Gene Family in Melon (Cucumis melo L.): CmCXE7 as a Cold-Responsive Regulator of Ester Metabolism
BibTeX
@article{galanova2026identification,
title = {{Identification and characterization of novel Faecalibacterium prausnitzii strains from infant gut microbiota with potential pharmabiotic applications}},
author = {Olesya O. Galanova and Mikhail D. Akulinin and Daria A. Troshina and Alexey S. Kovtun and Maya V. Odorskaya and Diana A. Reznikova and Olga B. Bekker and Vera V. Muravieva and Pavel Denisov and Ksenia N. Zhigalova and Roman V. Izyumov and Alexey B. Gordeev and Bayr O. Bembeeva and Elena L. Isaeva and Viktoria A. Kuznetsova and Natalia L. Starodubtseva and Evgenii N. Kukaev and Alexey A. Vatlin and Tatiana V. Priputnevich and Valery N. Danilenko and Gennady T. Sukhikh},
journal = {Frontiers in Microbiology},
year = {2026},
month = nov,
doi = {10.3389/fmicb.2026.1911184},
url = {https://www.frontiersin.org/articles/10.3389/fmicb.2026.1911184},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Identification and characterization of novel Faecalibacterium prausnitzii strains from infant gut microbiota with potential pharmabiotic applications
AU - Olesya O. Galanova
AU - Mikhail D. Akulinin
AU - Daria A. Troshina
AU - Alexey S. Kovtun
AU - Maya V. Odorskaya
AU - Diana A. Reznikova
AU - Olga B. Bekker
AU - Vera V. Muravieva
AU - Pavel Denisov
AU - Ksenia N. Zhigalova
AU - Roman V. Izyumov
AU - Alexey B. Gordeev
AU - Bayr O. Bembeeva
AU - Elena L. Isaeva
AU - Viktoria A. Kuznetsova
AU - Natalia L. Starodubtseva
AU - Evgenii N. Kukaev
AU - Alexey A. Vatlin
AU - Tatiana V. Priputnevich
AU - Valery N. Danilenko
AU - Gennady T. Sukhikh
PY - 2026
DA - 2026/11/04
JO - Frontiers in Microbiology
DO - 10.3389/fmicb.2026.1911184
UR - https://www.frontiersin.org/articles/10.3389/fmicb.2026.1911184
AB - Faecalibacterium prausnitzii is a dominant commensal bacterium in the human gut, widely known for its production of bioactive metabolites and currently considered a potential pharmabiotic for the treatment of various human diseases. In this study, ten novel strains of Faecalibacterium prausnitzii were isolated from stool samples of Russian infants and characterized using whole genome sequencing and metabolomic analyses. Comparative genomic analysis revealed an open pangenome structure and significant strain-specific variability, reflecting the strains’ high adaptive potential within the human host and confirming the heterogeneity of this species. Four isolates (MSK-01, MSK-05, MSK-07, MSK-09) exhibited elevated butyrate production, and MSK-01 additionally displayed enhanced formate synthesis. The previously developed catalog of genes with anti-inflammatory, immune, and neuromodulatory activity was used for in silico analysis and targeted annotation of sequenced genomes. In silico analysis confirmed the presence of genes associated with anti-inflammatory, antioxidant, and neuromodulatory metabolites. Strains MSK-07 and MSK-09 were selected as the top candidates for development as infant pharmabiotics. These results expand on previously described findings on the genetic diversity of Faecalibacterium prausnitzii and identify promising strains with high pharmabiotic potential for future human therapy. These findings allow us to proceed to the next stages of selection and development of pharmabiotics for microbiome correction.
SN - 1664-302X
ER -